Pulmonary hypertension clinical trials have almost traditionally focused primarily on Group 1 patients. However, recent interest has been built around non-Group 1 patients or on subgroups of the Group 1 category. This expert roundtable explores some of the issues particular to PH patients not often found in the idiopathic groups often used for clinical trials.